Clinical review about TRAb assay's history

Autoimmunity Reviews

Volumn 9, Issue 10, 2010, Pages 695-700

  Zöphel, Klaus ^a   Roggenbuck, Dirk ^b   Schott, Matthias ^c  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b GA GENERIC ASSAYS GMBH   (Germany)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Autoimmune thyroid diseases; Diagnostic sensitivity; Functional sensitivity; Graves' disease; M22; Thyroid autoantibodies; TRAb; TSH receptor

Indexed keywords

AUTOANTIBODY; DETERGENT; MONOCLONAL ANTIBODY; THYROTROPIN RECEPTOR ANTIBODY;

DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; ENDOCRINE OPHTHALMOPATHY; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; IMMUNE FUNCTION TEST; IMMUNOASSAY; POSTPARTUM THYROIDITIS; PREDICTION; REVIEW; SERODIAGNOSIS; SILENT THYROIDITIS; THYROIDITIS;

ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; DIAGNOSIS, DIFFERENTIAL; GRAVES DISEASE; HUMANS; ORGAN SPECIFICITY; PROGNOSIS; RECEPTORS, THYROTROPIN; SEROLOGIC TESTS; THYROIDITIS, AUTOIMMUNE;

EID: 77955273867     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2010.05.021     Document Type: Review

References (73)

1. Adams D.D., Purves H.D. Abnormal responses in the assay of thyrotropin. Proc Univ Otago Med Sch 1956, 34:11-15.
2. Kriss J.P., Pleshakov V., Chien J.R. Isolation and identification of the long-acting thyroid stimulator and its relation to hyperthyroidism and circumscribed pretibial myxedema. J Clin Endocrinol Metab 1964, 24:1005-1028.
3. Furmaniak J., Rees Smith B. The structure of thyroid autoantigens. Autoimmunity 1990, 7:63-80.
4. Jacobson D.L., Gange S.J., Rose N.R., Graham N.M. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997, 84:223-243.
5. Chen C.R., Pichurin P., Nagayama Y., Latrofa F., Rapoport B., McLachlan S.M. The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim. J Clin Invest 2003, 111(12):1897-1904.
6. Zhang M., Tong K.P., Fremont V., Chen J., Narayan P., Puett D., et al. The extracellular domain suppresses constitutive activity of the transmembrane domain of the human TSH receptor: implications for hormone-receptor interaction and antagonist design. Endocrinology 2000, 141(9):3514-3517.
7. Vlaeminck-Guillem V., Ho S.C., Rodien P., Vassart G., Costagliola S. Activation of the cAMP pathway by the TSH receptor involves switching of the ectodomain from a tethered inverse agonist to an agonist. Mol Endocrinol 2002, 16(4):736-746.
8. Quellari M., Desroches A., Beau I., Beaudeux E., Misrahi M. Role of cleavage and shedding in human thyrotropin receptor function and trafficking. Eur J Biochem 2003, 270(17):3486-3497.
9. Ciullo I., Latif R., Graves P., Davies T.F. Functional assessment of the thyrotropin receptor-beta subunit. Endocrinology 2003, 144(7):3176-3181.
10. Michalek K., Morshed S.A., Latif R., Davies T.F. TSH receptor autoantibodies. Autoimmun Rev 2009, 9:113-116.
11. Morgenthaler N.G., Ho S.C., Minich W.B. Stimulating and blocking thyroid-stimulating hormone (TSH) receptor autoantibodies from patients with Graves' disease and autoimmune hypothyroidism have very similar concentration, TSH receptor affinity, and binding sites. J Clin Endocrinol Metab 2007, 92(3):1058-1065.
12. Schwarz-Lauer L., Chazenbalk G.D., Mclachlan S.M., Ochi Y., Nagayama Y., Rapoport B. Evidence for a simplified view of autoantibody interactions with the thyrotropin receptor. Thyroid 2002, 12(2):115-120.
13. Ando T., Latif R., Daniel S., Eguchi K., Davies T.F. Dissecting linear and conformational epitopes on the native thyrotropin receptor. Endocrinology 2004, 145(11):5185-5193.
14. Sanders J., Chirgadze D.Y., Sanders P., Baker S., Sullivan A., Bhardwaja A., et al. Crystal structure of the TSH receptor in complex with a thyroid-stimulating autoantibody. Thyroid 2007, 17(5):395-410.
15. Saravanan P., Dayan C.M. Thyroid autoantibodies. Endocrinol Metab Clin N Am 2001, 30:315-337.
16. Sanders J., Oda Y., Roberts S.-A., Furmaniak J., Rees Smith B. Understanding the thyrotropin receptor function-structure relationship. (Hrsg) Baillière's Clin Endocrinol Metab, Baillière's London 1997, 11:451-479.
17. Rees Smith B., Hall R. Thyroid-stimulating immunoglobulins in Graves' disease. Lancet 1974, 2:427-431.
18. Shewring G., Rees Smith B. An improved radioreceptor assay for TSH receptor antibodies. Clin Endocrinol (Oxf) 1982, 17:409-417.
19. Southgate K., Creagh F.M., Teece M., Kingswood C., Rees Smith B. A receptor assay for the measurement of TSH receptor antibodies in unextracted serum. Clin Endocrinol 1984, 20:539-543.
20. Kakinuma A., Morimoto I., Kuroda T., Fujihira T., Eto S., McLachlan S.M., et al. Comparison of recombinant human thyrotropin receptors versus porcine thyrotropin receptors in the thyrotropin binding inhibition assay for thyrotropin receptor autoantibodies. Thyroid 1999, 9:849-855.
21. Sanders J., Oda Y., Roberts S., Kiddie A., Richards T., Bolton J., et al. The interaction of TSH receptor autoantibodies with 125I-labelled TSH receptor. J Clin Endocrinol Metab 1999, 84:3797-3802.
22. Costagliola S., Morgenthaler N.G., Hoermann R., Badenhoop K., Struck J., Freitag D., et al. Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease. J Clin Endocrinol Metab 1999, 84:90-97.
23. Bolton J., Sanders J., Oda Y., Chapman C., Konno R., Furmaniak J., et al. Measurement of thyroid-stimulating hormone receptor autoantibodies by ELISA. Clin Chem 1999, 45:2285-2287.
24. Massart C., Orgiazzi J., Maugendre D. Clinical validity of a new commercial method for detection of TSH-receptor binding antibodies in sera from patients with Graves' disease treated with antithyroid drugs. Clin Chim Acta 2001, 304:39-47.
25. Meller J., Schreivogel I., Bergmann A., Morgenthaler N., Hüfner M., Becker W. Clinical implications of a new TSH receptor antibody assay (DYNOtest TRAKhuman) in autoimmune thyroid diseases. Nuklearmedizin 2000, 39:5-9.
26. Meller J., Jauho A., Hüfner M., Gratz S., Becker W. Disseminated thyroid autonomy or Graves' disease: reevaluation by a second generation TSH receptor antibody assay. Thyroid 2000, 10:1073-1079.
27. Bülow Pedersen I., Knudsen N., Perrild H., Ovesen L., Laurberg P. TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves' disease and multinodular toxic goitre: a comparison of two competitive binding assays. Clin Endocrinol 2001, 55:381-390.
28. Giovanella L., Ceriani L., Garancini S. Evaluation of the 2nd generation radio-receptional assay for anti-TSH-receptor antibodies (TRAb) in autoimmune thyroid diseases. Comparison with 1st generation and anti-thyroperoxidase antibodies (AbTPO). Q J Nucl Med 2001, 45:115-119.
29. Kamijo K. TSH-receptor antibody measurement in patients with various thyrotoxicosis and Hashimoto's thyroiditis: a comparison of two two-step assays, coated plate ELISA using porcine TSH-receptor and coated tube radioassay using human recombinant TSH-receptor. Endocr J 2003, 50:113-116.
30. Hirooka Y., Li C., Takagi J., Gotoh M., Habu S., Yasaka-Nomura T., et al. Comparison of new different assay systems for thyrotropin receptor antibodies with reference to thyroid-stimulating antibodies and thyroid stimulation blocking antibodies in Graves' disease. Int J Clin Pharm Res 2004, 24:111-116.
31. Okamoto Y., Tanigawa S.I., Ishikawa K., Hamada N. TSH receptor antibody measurements and prediction of remission in Graves' disease patients treated with minimum maintenance doses of antithyroid drugs. Endocr J 2006, 53:467-472.
32. Farid N.R., Szkudlinski M.W. Minireview: structural and functional evolution of the thyrotropin receptor. Endocrinology 2004, 145:4048-4057.
33. Rees Smith B. Thyroid autoantibodies. Scand J Clin Lab Invest 2001, 61(Suppl. 235):45-52.
34. Zöphel K., von Landenberg P., Roggenbuck D., Wunderlich G., Kotzerke J., Lackner K.J. Are porcine and human TSH receptor antibody measurements comparable?. Clin Lab 2008, 54:1-8.
35. Zöphel K., Grüning T., Roggenbuck D., Wunderlich G., Kotzerke J. On specificity of 2nd generation TSH receptor autoantibody measurements. Clin Lab 2008, 54:243-249.
36. Hermsen D., Liu C., Domberg J., Graeber C., Feldkamp J., Duan Y., et al. Comparison of a solid phase human- versus porcine- thyrotropin receptor-based immunoassay for the measurement of thyrotropin receptor antibodies in patients with thyroid diseases. Exp Clin Endocrinol Diab 2008, 116(Suppl 1):S59-S63.
37. Zöphel K., Wunderlich G., Koch R., Franke W.G. Measurement of thyrotropin receptor antibodies (TRAK) with a second generation assay in patients with Graves' disease. Nuklearmedizin 2000, 39:113-120.
38. Sanders J., Jeffreys J., Depraetere H., Richards T., Evans M., Kiddie A., et al. Thyroid-stimulating monoclonal antibodies. Thyroid 2002, 12:1043-1050.
39. Sanders J., Evans M., Premawardhana L.D., Depraetere H., Jeffreys J., Richards T., et al. Human monoclonal thyroid stimulating autoantibody. Lancet 2003, 362:126-128.
40. Sanders J., Jeffreys J., Depraetere H., Evans M., Richards T., Kiddie A., et al. Characteristics of a human monoclonal autoantibody to the thyrotropin receptor: sequence structure and function. Thyroid 2004, 14:560-570.
41. Zöphel K., Wunderlich G., Kotzerke J., von Landenberg P., Roggenbuck D. M22 based (manual) ELISA for TSH-receptor antibody (TRAb) measurement is more sensitive than 2nd generation TRAb assays. Clin Chim Acta 2009, 403:266.
42. Rees Smith B., Bolton J., Young S., Collyer A., Weeden A., Bradbury J., et al. A new assay for thyrotropin receptor autoantibodies. Thyroid 2004, 14:830-835.
43. Spencer C.A., Takeuchi M., Kazarosyan M. Current status and performance goals for serum thyrotropin (TSH) assays. Clin Chem 1996, 42:140-145.
44. Zöphel K., Roggenbuck D., von Landenberg P., Wunderlich G., Grüning T., Kotzerke J., et al. TSH receptor antibody (TRAb) assays based on the human monoclonal autoantibody M22 are more sensitive than bovine TSH based assays. Horm Metab Res 2010, 42:65-69.
45. Liu C., Hermsen D., Domberg J., Graeber C., Hautzel H., Duan Y., et al. Comparison of M22-based ELISA and human-TSH-receptor-based luminescence assay for the measurement of thyrotropin receptor antibodies in patients with thyroid diseases. Horm Metab Res 2008, 40:79-83.
46. Hermsen D., Broecker-Preuss M., Casati M., Mas J.C., Eckstein A., Gassner D., et al. Technical evaluation of the first fully automated assay for the detection of TSH receptor autoantibodies. Clin Chim Acta 2009, 401:84-89.
47. Schott M., Hermsen D., Broecker-Preuss M., Casati M., Mas J.C., Eckstein A., et al. Clinical value of the first automated TSH receptor autoantibody assay for the diagnosis of Graves' disease: an international multicentre trial. Clin Endocrinol (Oxf) 2009, 71:566-573.
48. Hermsen D., Eckstein A., Schinner S., Willenberg H.S., Thiel A., Scherbaum W.A., et al. Reproducibility of Elecsys anti-TSHR test results in a lot-to-lot comparison. Horm Metab Res 2010, 42(4):295-297.
49. Massart C., Sapin R., Gibassier J., Agin A., d'Herbomez M. Intermethod variability in TSH-receptor antibody measurement: implication for the diagnosis of Graves disease and for the follow-up of Graves ophthalmopathy. Clin Chem 2009, 55:183-186.
50. Feldt-Rasmussen U. Analytical and clinical performance goals for testing autoantibodies to thyroperoxidase, thyroglobulin, and thyrotropin receptor. Clin Chem 1996, 42:160-163.
51. Takasu N., Oshiro C., Akamine H., Komiya I., Nagata A., Sato Y., et al. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects. J Endocrinol Invest 1997, 20:452-461.
52. Zouvanis M., Panz V.R., Kalk W.J., Joffe B.I. Thyrotropin receptor antibodies in black South African patients with Graves' disease and their response to medical therapy. J Endocrinol Invest 1998, 21:771-774.
53. Ilicki A., Gamstedt A., Karlsson F.A. Hyperthyroid Graves' disease without detectable thyrotropin receptor antibodies. J Clin Endocrinol Metab 1992, 74:1090-1094.
54. Kawai K., Tamai H., Matsubayashi S., Mukuta T., Morita T., Kubo C., et al. A study of untreated Graves' patients with undetectable TSH binding inhibitor immunoglobulins and the effect of anti-thyroid drugs. Clin Endocrinol (Oxf) 1995, 43:551-556.
55. Dietlein M., Dressler J., Grünwald F., Joseph K., Leisner B., Moser E., et al. Deutsche Gesellschaft für Nuklearmedizin. [Guideline for in vivo- and in vitro procedures for thyroid diseases (version 2)]. Nuklearmedizin 2003, 42:109-115.
56. Dietlein M., Dressler J., Grünwald F., Leisner B., Moser E., Reiners C., et al. Guideline for radioiodine therapy for benign thyroid diseases (version 4). Nuklearmedizin 2007, 46:220-223.
57. Eckstein A., Mann K., Kahaly G.J., Grussendorf M., Reiners C., Feldkamp J., et al. Role of TSH receptor autoantibodies for the diagnosis of Graves' disease and for the prediction of the course of hyperthyroidism and ophthalmopathy. Recommendations of the Thyroid Section of the German Society of Endocrinology. Med Klin (Munich) 2009, 104:343-348.
58. Laurberg P., Wallin G., Tallstedt L., Abraham-Nordling M., Lundell G., Tørring O. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 2008, 158:69-75.
59. Hoermann R., Quadbeck B., Roggenbuck U., Szabolcs I., Pfeilschifter J., Meng W., et al. Relapse of Graves' disease after successful outcome of antithyroid drug therapy: results of a prospective randomized study on the use of levothyroxine. Thyroid 2002, 12:1119-1128.
60. Quadbeck B., Hoermann R., Roggenbuck U., Hahn S., Mann K., Janssen O.E., et al. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease. Thyroid 2005, 15:1047-1054.
61. Schott M., Morgenthaler N.G., Fritzen R., Feldkamp J., Willenberg H.S., Scherbaum W.A., et al. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease. Horm Metab Res 2004, 36:92-96.
62. Quadbeck B., Hoermann R., Hahn S., Roggenbuck U., Mann K., Janssen O.E. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment. Horm Metab Res 2005, 37:745-750.
63. Carella C., Mazziotti G., Sorvillo F., Piscopo M., Cioffi M., Pilla P., et al. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period. Thyroid 2006, 16:295-302.
64. Zimmermann-Belsing T., Nygaard B., Rasmussen A.K., Feldt-Rasmussen U. Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves' disease. Eur J Endocrinol 2002, 146:173-177.
65. Davies T.F., Roti E., Braverman L.E., DeGroot L.J. Thyroid controversy-stimulating antibodies. J Clin Endocrinol Metab 1998, 83:3777-3785.
66. Eckstein A.K., Plicht M., Lax H., Neuhäuser M., Mann K., Lederbogen S., et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 2006 Sep, 91:3464-3470.
67. Hollowell J.G., Staehling N.W., Flanders W.D., Hannon W.H., Gunter E.W., Spencer C.A., et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002, 87:489-499.
68. Takasu N., Yamada T., Takasu M., Komiya I., Nagasawa Y., Asawa T., et al. Disappearance of thyrotropin-blocking antibodies and spontaneous recovery from hypothyroidism in autoimmune thyroiditis. N Engl J Med 1992, 326:513-518.
69. Tamaki H., Amino N., Kimura M., Hidaka Y., Takeoka K., Miyai K. Low prevalence of thyrotropin receptor antibody in primary hypothyroidism in Japan. J Clin Endocrinol Metab 1990, 71:1382-1386.
70. Dayan C.M. Interpretation of thyroid function tests. Lancet 2001, 357:619-624.
71. Fabris M., Grimaldi F., Villalta D., Picierno A., Fabro C., Bolzan M., et al. BLyS and April serum levels in patients with autoimmune thyroid diseases. Autoimmun Rev 2010, 9(3):165-169.
72. Parmentier M., Libert F., Maenhaut C., Lefort A., Gérard C., Perret J., et al. Molecular cloning of the thyrotropin receptor. Science 1989, 246:1620-1622.
73. Kubota S., Gunji K., Ackrell B.A., Cochran B., Stolarski C., Wengrowicz S., et al. The 64-kilodalton eye muscle protein is the flavoprotein subunit of mitochondrial succinate dehydrogenase: the corresponding serum antibodies are good markers of an immune-mediated damage to the eye muscle in patients with Graves' hyperthyroidism. J Clin Endocrinol Metab 1998, 83:443-447.